Metabolic · AMPK activator · Compounded 503A
AICAR: the AMPK-activator exercise mimetic.
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) is a small molecule that directly activates AMPK — the cellular energy sensor switched on by exercise and caloric restriction. In animal studies it reproduces several endurance-training adaptations without exercise, which is why it sits at the intersection of metabolic medicine and longevity research.
What AICAR is
AICAR (also called acadesine) is a nucleotide analog that is taken up by cells and phosphorylated to ZMP — a structural mimic of AMP. ZMP binds and allosterically activates AMP-activated protein kinase (AMPK).
AMPK is the master sensor of cellular energy balance. When ATP runs low (during exercise, fasting, or stress), AMPK turns on catabolic programs — glucose uptake, fatty acid oxidation, mitochondrial biogenesis — and turns off anabolic programs.
AICAR is not a peptide. It is included in kindr's longevity catalog because it is dispensed through the same compounded pharmacy channel and addresses overlapping metabolic and endurance goals.
How it works
Once inside the cell, AICAR is phosphorylated to ZMP, which occupies the AMP-binding site on AMPK and locks it in an active conformation — without any change to actual ATP/AMP ratios.
Active AMPK drives GLUT4 translocation (insulin-independent glucose uptake), increases fatty-acid oxidation, suppresses lipogenesis and cholesterol synthesis, and turns on PGC-1α — the master regulator of mitochondrial biogenesis.
In the landmark 2008 Narkar et al. Cell study, sedentary mice given AICAR for 4 weeks improved running endurance ~44% — the original 'exercise in a pill' result.
What patients use it for
AMPK activation
Direct, dose-dependent AMPK activation — the cellular energy sensor that exercise and metformin act through.
Endurance capacity
In animal models, increases time-to-fatigue and oxidative muscle fiber content even without training.
Glucose uptake
Insulin-independent GLUT4 translocation — relevant in insulin resistance and metabolic syndrome.
Mitochondrial biogenesis
Upregulates PGC-1α and downstream mitochondrial gene programs — overlapping with the SLU-PP-332 and MOTS-c mechanisms.
Evidence summary
Narkar VA et al. (Cell, 2008) — the headline paper showing AICAR-treated sedentary mice gained endurance equivalent to trained controls.
Cuthbertson DJ et al. (Diabetes, 2007) demonstrated AICAR's effect on glucose uptake in human skeletal muscle.
WADA banned AICAR in 2009 due to its athletic-performance implications — strong indirect evidence the mechanism translates to humans.
Direct large-scale human RCT data for chronic AICAR remains limited; longevity-axis use is genuinely investigational.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Subcutaneous injection is the typical compounded-practice route.
Course-based protocols (4–8 weeks) timed to training cycles are common in practice.
Not FDA-approved for any indication; compounded through licensed 503A pharmacies under physician prescription.
Safety and contraindications
Short-term safety in IV cardiac studies was acceptable; long-term metabolic-use safety is not characterized in humans.
Theoretical risk: chronic AMPK activation may have unintended effects on growth signaling (mTOR suppression) — the trade-off between longevity and anabolism.
Contraindications: pregnancy, lactation, active malignancy (AMPK biology in cancer is bidirectional), pediatric use.
Who it's typically considered for
- Adults with metabolic dysfunction and limited exercise capacity (specialist supervision)
- Patients pursuing longevity-axis interventions comfortable with early-evidence small molecules
- Patients pairing with structured training rather than substituting for it
Frequently asked questions
Is AICAR a peptide?
No — it is a small-molecule nucleotide analog. Included in our catalog because it is compounded and prescribed through the same pathway.
AICAR vs metformin?
Both ultimately raise AMPK activity, but through different upstream mechanisms. Metformin has decades of human safety data and an FDA approval; AICAR does not.
Will AICAR replace exercise?
No. It reproduces some molecular signatures of endurance training but not the cardiovascular, musculoskeletal, or neurological adaptations.
Is AICAR banned in sport?
Yes — WADA lists it as a prohibited substance (S4 metabolic modulator). Competitive athletes should not use it.
Is AICAR FDA-approved?
No. It is investigational; compounded use is off-label under physician supervision.
AICAR vs SLU-PP-332?
Both target the exercise-mimetic space through complementary mechanisms — AICAR activates AMPK directly; SLU-PP-332 activates the ERR transcription factors. Some protocols combine them.
Sources
- Narkar VA et al. AMPK and PPARδ agonists are exercise mimetics. Cell (2008). — pubmed.ncbi.nlm.nih.gov/18674809
- Cuthbertson DJ et al. AICAR-induced glucose uptake in human skeletal muscle. Diabetes (2007). — pubmed.ncbi.nlm.nih.gov/17327455
- Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes (2013). — pubmed.ncbi.nlm.nih.gov/23804760
Considering AICAR?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Start your longevity intake →Related peptides
Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026
Last reviewed May 10, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.